BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 25812534)

  • 21. [Diagnostic value of positron emission tomography (PET) in clinical oncology].
    Czech N; Brenner W; Kampen WU; Henze E
    Dtsch Med Wochenschr; 2000 May; 125(18):565-7. PubMed ID: 10835983
    [No Abstract]   [Full Text] [Related]  

  • 22. PET/CT in oncology: a major technology for cancer care.
    Ell PJ
    Chang Gung Med J; 2005 May; 28(5):274-83. PubMed ID: 16086542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Utility of brain FDG-PET in primary CNS lymphoma.
    Mohile NA; Deangelis LM; Abrey LE
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):818-20, 840. PubMed ID: 19194366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma.
    Delbeke D
    J Nucl Med; 1999 Apr; 40(4):591-603. PubMed ID: 10210218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer.
    Deniaud-Alexandre E; Touboul E; Lerouge D; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Keraudy K; Kerrou K; Montravers F; Milleron B; Lebeau B; Talbot JN
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1432-41. PubMed ID: 16125870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 18-Fluorodeoxyglucose positron emission tomography as a tool for response prediction in solid tumours.
    De Maeseneer DJ; Lambert B; Surmont V; Geboes K; Rottey SW
    Acta Clin Belg; 2010; 65(5):291-9. PubMed ID: 21128554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PET in oncology: will it replace the other modalities?
    Hoh CK; Schiepers C; Seltzer MA; Gambhir SS; Silverman DH; Czernin J; Maddahi J; Phelps ME
    Semin Nucl Med; 1997 Apr; 27(2):94-106. PubMed ID: 9144854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cost-effective PET scans in oncology].
    Kálvin B; Fekésházy A; Lengyel Z; Szakáll S; Agoston P; Lengyel E; Székely J; Várady E; Galuska L; Trón L; Esik O
    Orv Hetil; 2002 May; 143(21 Suppl 3):1255-61. PubMed ID: 12077909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. First clinical results of (D)-18F-Fluoromethyltyrosine (BAY 86-9596) PET/CT in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.
    Burger IA; Zitzmann-Kolbe S; Pruim J; Friebe M; Graham K; Stephens A; Dinkelborg L; Kowal K; Schibli R; Luurtsema G; Maas B; Horn-Tutic M; Haerle SK; Wiegers J; Schaefer NG; Hany TF; von Schulthess GK
    J Nucl Med; 2014 Nov; 55(11):1778-85. PubMed ID: 25256060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Impact of [18F]-FDG-PET on medical decision making in oncology: evaluation by the referring physicians during the opening year].
    Talbot JN; Rain JD; Meignan M; Askienazy S; Grall Y; Bok B; Misset JL
    Bull Cancer; 2002 Mar; 89(3):313-21. PubMed ID: 11940470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence.
    Deleau C; Buecher B; Rousseau C; Kraeber-Bodéré F; Flamant M; des Varannes SB; Frampas E; Galmiche JP; Matysiak-Budnik T
    Eur J Gastroenterol Hepatol; 2011 Mar; 23(3):275-81. PubMed ID: 21304319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
    Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
    Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bilateral hilar foci on 18F-FDG PET scan in patients without lung cancer: variables associated with benign and malignant etiology.
    Karam M; Roberts-Klein S; Shet N; Chang J; Feustel P
    J Nucl Med; 2008 Sep; 49(9):1429-36. PubMed ID: 18765585
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer.
    Messa C; Ceresoli GL; Rizzo G; Artioli D; Cattaneo M; Castellone P; Gregorc V; Picchio M; Landoni C; Fazio F
    Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):259-66. PubMed ID: 16172572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
    Kitagawa Y; Nishizawa S; Sano K; Ogasawara T; Nakamura M; Sadato N; Yoshida M; Yonekura Y
    J Nucl Med; 2003 Feb; 44(2):198-206. PubMed ID: 12571209
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Positron emission tomography with [18F]fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma: a multicenter prospective study.
    Lonneux M; Hamoir M; Reychler H; Maingon P; Duvillard C; Calais G; Bridji B; Digue L; Toubeau M; Grégoire V
    J Clin Oncol; 2010 Mar; 28(7):1190-5. PubMed ID: 20124179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient.
    Lonneux M; Lawson G; Ide C; Bausart R; Remacle M; Pauwels S
    Laryngoscope; 2000 Sep; 110(9):1493-7. PubMed ID: 10983949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of 18F-fluoro-2-deoxyglucose positron emission tomography on treatment strategy and radiotherapy planning for stage I-II Hodgkin disease: a prospective multicenter study.
    Pommier P; Dussart S; Girinsky T; Chabaud S; Lagrange JL; Nguyen TD; Beckendorff V; D'Hombres A; Artignan X; Bondiau PY; Carrie C; Giammarile F
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):823-8. PubMed ID: 20452732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDG PET-CT in the management of primary breast lymphoma.
    Santra A; Kumar R; Reddy R; Halanaik D; Kumar R; Bal CS; Malhotra A
    Clin Nucl Med; 2009 Dec; 34(12):848-53. PubMed ID: 20139815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical significance of postradiotherapy [18F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer-a long-term outcome report.
    Yao M; Smith RB; Hoffman HT; Funk GF; Lu M; Menda Y; Graham MM; Buatti JM
    Int J Radiat Oncol Biol Phys; 2009 May; 74(1):9-14. PubMed ID: 18930358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.